Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report

BACKGROUND: Antitumor immunotherapy has become a major player in cancer therapy. Ipilimumab is a humanized monoclonal antibody against the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an important downregulator of T-cell activation. Ipilimumab has demonstrated tumor regression and improveme...

Descripción completa

Detalles Bibliográficos
Autores principales: Akel, Reem, Anouti, Bilal, Tfayli, Arafat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471790/
https://www.ncbi.nlm.nih.gov/pubmed/28626406
http://dx.doi.org/10.1159/000475709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471790/
https://www.ncbi.nlm.nih.gov/pubmed/28626406
http://dx.doi.org/10.1159/000475709

Ejemplares similares